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Abstract
Background: Interferon-gamma (IFN-g) Release Assays (IGRA) are more specific than the tuberculosis skin test (TST)
in the diagnosis of latent tuberculosis (TB) infection (LTBI). We present the performance of the QuantiFERON®-TB
Gold In-tube (QFT-TB) assay as diagnostic test and during follow-up of preventive TB therapy in outpatients from a
TB low-endemic country.
Methods: 481 persons with suspected TB infection were tested with QFT-TB. Thoracic X-ray and sputum samples
were performed and a questionnaire concerning risk factors for TB was filled. Three months of isoniazid and
rifampicin were given to patients with LTBI and QFT-TB tests were performed after three and 15 months.
Results: The QFT-TB test was positive in 30.8% (148/481) of the total, in 66.9% (111/166) of persons with origin from
a TB endemic country, in 71.4% (20/28) previously treated for TB and in 100% (15/15) of those diagnosed with active
TB with no inconclusive results. The QFT-TB test was more frequently positive in those with TST ≥ 15 mm (47.5%)
compared to TST 11-14 mm (21.3%) and TST 6-10 mm (10.5%), (p < 0.001). Origin from a TB endemic country (OR
6.82, 95% CI 1.73-26.82), recent stay in a TB endemic country (OR 1.32, 95% CI 1.09-1.59), duration of TB exposure (OR
1.59, 95% CI 1.14-2.22) and previous TB disease (OR 11.60, 95% CI 2.02-66.73) were all independently associated with a
positive QFT-TB test. After preventive therapy, 35/40 (87.5%) and 22/26 (84.6%) were still QFT-TB positive after three
and 15 months, respectively. IFN-g responses were comparable at start (mean 6.13 IU/ml ± SD 3.99) and after three
months (mean 5.65 IU/ml ± SD 3.66) and 15 months (mean 5.65 IU/ml ± SD 4.14), (p > 0.05).
Conclusion: Only one third of those with suspected TB infection had a positive QFT-TB test. Recent immigration
from TB endemic countries and long duration of exposure are risk factors for a positive QFT-TB test and these
groups should be targeted through screening. Since most patients remained QFT-TB positive after therapy, the test
should not be used to monitor the effect of preventive therapy. Prospective studies are needed in order to
determine the usefulness of IGRA tests during therapy.
Background
The Interferon-gamma (IFN-g) Release Assays (IGRA),
offering better specificity in the diagnosis of latent
tuberculosis (TB) infection (LTBI) than the tuberculosis
skin test (TST) [1-6], are now recommended in many
national TB programs in low-endemic countries [6-8].
There are two commercial assays available and although
T-SPOT.TB® seems to give higher sensitivities in immu-
nocompromised patients [9], the QuantiFERON®-TB
Gold In-tube (QFT-TB) is often the test of choice in the
clinical setting due to easier logistics when processing
samples. In a meta-analysis the pooled sensitivity
for QFT-TB was 70-78% and the specificity was
99% among non-BCG-vaccinated and 96% among BCG-
vaccinated persons. The authors conclude that the
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IGRAs have excellent specificity that is unaffected by
BCG vaccination [6].
Many studies have focused on the performance of the
IGRA tests in active TB [4] or in certain risk groups as
TB contacts [3,5], health-care workers [10] or in patients
treated with tumor necrosis factor-alfa (TNF-a) inhibi-
tors [11,12]. Fewer studies have been performed in out-
patient clinical settings including individuals referred for
various reasons according to clinical practise and
national guidelines [9]. All studies are limited by the
lack of a diagnostic gold standard for LTBI. The effect
of preventive therapy on IFN-g responses [13-16] and
the cost-effectiveness of the IGRA tests on this patient
population are still controversial [17,18]. Diel et al.
reported that QFT-TB is a more accurate indicator of
progression to active TB than TST [19]. Still, there is
limited data concerning the usefulness of the IGRA tests
to identify those individuals with LTBI who are at most
risk for developing active disease and therefore most
likely to benefit from preventive therapy [20].
Norway is a TB low-endemic country and the Norwe-
gian population has until 2009 been BCG vaccinated at
the age of fourteen, whereas the immigrant groups are
often vaccinated as infants. Further, non-tuberculous
mycobacteria (NTM) infections are also quite common
[21,22]. These factors cause difficulties in diagnosing
LTBI since the specificity of the TST test is low and
variable in the BCG-vaccinated population. Immigration
from TB high-endemic countries and increased global
travelling with possible TB exposure challenge the epi-
demic situation [23]. Thus, the various groups demon-
strating a positive TST test are very heterogeneous and
more reliable diagnostic tools are needed to identify
those with LTBI in order to offer proper preventive
therapy and follow-up.
We performed a study to evaluate the usefulness of
the QFT-TB test in the diagnosis of active and latent
TB in a typical outpatient clinic in a TB low-endemic
country. We analysed the various risk factors for a posi-
tive QFT-TB test. Further, we studied the reversion
rates of the QFT-TB test and the IFN-g responses right
after and one year after ended preventive TB therapy in
QFT-TB positive individuals.
Methods
Study participants
Persons referred to the TB outpatient clinic at Hauke-
land University Hospital, Bergen, Norway in the period
January 2006 to January 2007 were included in the
study. The participants were referred for medical evalua-
tion of latent or active TB based on a positive TST and/
or suspected exposure of TB according to national
guidelines for screening [24]. The TST was performed
in the primary health care institutions with purified
protein derivative (PPD) RT 23 (2 TU) (Statens Serum
Institute, Copenhagen, Denmark) and read after 72
hours. A cut-off value of ≥ 6 mm induration was consid-
ered a positive test. According to national guidelines,
persons with TST reactions in the range of 6-14 mm
should be referred if any risk factor for TB is known.
Everyone demonstrating a TST of ≥ 15 mm should be
evaluated by a specialist regardless of any known risk
factor for TB. There was a delay from TST testing to
specialist evaluation when active TB was not suspected.
Thus, most of the TST were performed at least three
months prior to inclusion. Thoracic X-ray and clinical
examination were performed and an induced sputum
sample was obtained for acid fast staining and culture in
all participants according to standard procedures at the
hospital.
When informed consent was given to participate in
the study, a questionnaire translated to the native lan-
guage regarding demographics, previous BCG vaccina-
tion and TST results, risk of exposure to TB and travel
history was filled. The BCG vaccine status was estab-
lished by self-reporting and the observation of a BCG
scar by the specialist. The participants were divided in
three groups: 1) from non-TB endemic country, 2) from
non-TB endemic country/visited a TB endemic country
and 3) from TB endemic country. The youngest partici-
pant was nine years old. Thus, age was categorised into
six groups (9-19 years, 20-29 years, 30-39 years, 40-49
years, 50-59 years and ≥ 60 years). Duration of exposure
was categorised into six groups (< 1 day, 1 to 6 days, 1
to < 4 weeks, 1 to < 2 months, 2 to < 3 months, ≥ 3
months). Time since last stay in a TB endemic country,
time since exposure of TB and time since vaccination
were all categorised as < 1 year, 1 to < 2 years, 2 to < 3
years, 3 to < 5 years, 5 to < 10 years, 10 to < 20 years
and then in 10 year intervals. Preventive therapy with
isoniazid and rifampicin for three months were started
based on national guidelines [24]. The patients were fol-
lowed with repetitive QFT-TB tests after three months
and 15 months. Routinely HIV-test was not performed,
but one of the participants was known HIV positive.
The study was approved by the Regional Ethics Com-
mittee for Medical Research and permission was given
from the Norwegian Data Inspectorate. Written
informed consent was given before inclusion in the
study.
QuantiFERON-TB Gold In-tube assay
One ml of whole blood was added to each of the three
QFT-TB tubes; TB antigen (ESAT-6, CFP-10 and TB
7.7), mitogen positive control (phytohemagglutinin
[PHA]) and a negative control. The tubes were treated
as recommended by the manufacturer (Cellestis Ltd.,
Victoria, Australia) and the IFN-g concentrations
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(IU/mL) in plasma was measured by an ELISA reader
and calculated by the ‘QFT-TB-analysis Software’. An
IFN-g ≥ 0.35 IU/ml (TB antigens minus negative con-
trol) was considered a positive test. A determinate test
must have mitogen minus negative control ≥ 0.5 IU/ml
and/or TB antigens minus negative control ≥ 0.35 IU/
ml. Values > 10 IU/ml was treated as 10 IU/ml due to
inaccurately of the ELISA assay above this level.
Statistics
Statistical analysis was performed using Stata 11 (Stata
Corporation, College Station, Texas, US). Data are pre-
sented as mean values with range and standard deviation
(SD). Univariate assessment of risk factors for positive
QFT-TB test was done by Chi square test and t test as
appropriate. Univariate odds ratios (OR) were obtained
by applying logistic regression on each variable separately
and presented with 95% confidence intervals (CI).
Multivariate analysis of risk factors for positive QFT-
TB test was performed by logistic regression. All vari-
ables in the univariate analysis were included in the mul-
tivariate model. Since observations with missing values
are automatically removed from logistic regression mod-
els, only 389 of the total of 481 observations remained in
the final multivariate model. The observation “duration
of exposure” had a particularly high number of missing
values (n = 63) and was responsible for a large part of the
missing values in the final model. We performed the
logistic regression on the final model with and without
that variable, and found that excluding or including it did
not significantly alter the findings in the model.
A priori, we considered the most important potential
interactions in the model to be those between BCG vac-
cine status and other explanatory variables. We assessed
all these potential interactions and did not find any signifi-
cant interactions between BCG vaccine status and any of
the other explanatory variables. Trends of QFT-TB values
over time were assessed by Wilcoxon rank-sum test.
Results
Epidemiological and clinical data
A total of 481 persons referred to the TB outpatient
clinic for examination of possible TB infection were
included in the study (Table 1). Fifteen patients were
diagnosed with new active TB and 444 were suspected
of latent TB defined by a positive TST ≥ 6 mm. Fifty-
four had thoracic X-ray findings that needed evaluation
for possible active TB. This was typically found in the
groups of previous TB disease (7/8) or with origin from
a TB endemic country (18/86). Induced sputum was
obtained from all the participants and twelve had posi-
tive culture of M. tuberculosis and one of M. fortuitum.
Two additional patients were regarded as active TB dis-
ease based on X-ray findings and one patient was
diagnosed with glandular TB. Four of the patients with
active TB, two of them with positive TB culture, demon-
strated normal X-rays. Among the 15 patients with
active TB, 13 was from a TB endemic country (mean
5.2 years since arrival Norway, range 0-31, SD ± 8.1),
one had parents from a TB endemic country, but was
born in Norway and one was ethnical Norwegian.
In a total of 435 (90.4%) persons a TST was performed
before referral, whereas in 46 (9.6%) persons no TST was
obtained, mainly because of documented previously
strong response. The mean TST value for the total group
was 13.3 mm (range 0-30). All patients with active TB
had a positive TST (mean 18 mm, range 10-24 mm).
The epidemiological data are as described in Table 2. A
total of 166 persons (34.5%) were born in a non-western
TB high (≥ 100/100 000) or intermediate (10-100/100
000) prevalence country, the majority from sub-Saharan
Africa or Southeast Asia. The mean time since immigra-
tion to Norway was 5.5 years (range 0-31, SD ± 6.7).
Table 1 Indications for Tuberculin skin test screening
and/or referral to clinical specialist evaluation (n = 481)
Screening No %
Contact Investigation*) 264 55.1
Immigrants*) 86 17.9
Health-care workers**) 7 1.5
School children before BCG vaccination 27 5.6
Before treatment with TNF-a inhibitor*) 64 13.3
HIV-1 infection 1 0.2
Clinical evaluation
Thoracic X-ray findings (only) 19 3.9
Previous TB disease (only) 8 1.7
Suspected extrapulmonary TB 5 1.0
TNF-a = tumor necrosis factor-alfa.
*) Including persons with previous TB and/or X-ray findings.
**) Working ≥ 3 months in a TB endemic country.
Table 2 Characteristics of study participants (n = 481)
Characteristics No %
Age; mean (range) 39 (9-87)
Gender
Male 196 40.7
Female 285 59.3
Origin
Norway with western parents 296 61.5
Another western country 7 1.5
Parents from TB endemic country 12 2.5
TB endemic country 166 34.5
Stay in TB endemic country 309 64.0
Exposure of TB 261 54.6
BCG vaccinated 423 87.9
BCG scar 356 74.0
Previous TB 28 5.8
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A total of 309 (64.0%) of the participants reported stay in
a TB endemic country, but only 208 (44.7%) stayed in a
period of 3 months or more and of these only 38 were
ethnically Norwegians. The mean time since the last visit
was 5 years (range 0-47, SD ± 7.3).
Altogether 261 (54.6%) of the participants reported
that they had been exposed to a known case of TB, the
majority referred as part of a contact investigation.
However, the majority of persons from TB endemic
countries and seven of the 15 patients diagnosed with
active TB during the study did not report on known
exposure. The mode of contact between the TB case
and the study participants was as shown in Table 3. The
mean time period since exposure was 3.8 years (range
0-61, SD ± 10.5).
A total of 423 (87.9%) persons reported that they had
received BCG vaccination, but scar was only found in
356 (74%). The mean time since vaccination was 27.7
years (range 1-64, SD ± 13.4), varying according to the
country of origin, since most of the foreign persons
were vaccinated as infants while BCG vaccination in
Norway is performed at the age of fourteen.
Twenty-eight (5.8%) of the participant had previously
experienced active TB disease and 26 reported that they
had received treatment from 3-24 months. Thirteen of
the treated were born in Norway or another western
country and thirteen came from TB endemic countries.
The mean time period since TB treatment was
10.3 years (range 1-22, SD ± 7.0) and 35.7 years (range
1-79, SD ± 27.3) for the immigrants and ethnical Nor-
wegians, respectively.
QuantiFERON-TB Gold and Tuberculin skin test results
The QFT-TB test was obtained at inclusion and the test
was conclusive for all participants with no indeterminate
results. All together 148 (30.8%) persons demonstrated a
positive test. The correlation between TST and QFT-TB
was as shown in Figure 1. The mean TST was 16.7 mm
(range 0-30) for the QFT-TB positive group and 11.7
mm (range 0-30), (p = 0.018) for the QFT-TB negative
group. The QFT-TB test was positive in all patients diag-
nosed with active TB, including the patient with M. for-
tuitum, but two patients had IFN-g values right above
cut-off, confirmed by repetitive testing (0.57-0.88 IU/ml).
The percentage of positive QFT-TB tests was highest in
persons with TST ≥ 15 mm (47.5%) and this was signifi-
cant compared to the groups with TST of 11-14 mm,
6-10 mm and < 6 mm (p < 0.001) (Table 4). The only
person with a positive QFT-TB and TST < 6 mm had
experienced active TB sixty years back, but had no find-
ings to support reactivation of infection. The eleven with
positive QFT-TB and TST ≤ 10 mm where either from
TB endemic countries or ethnical Norwegians with
known exposure, except one adolescent with a TST of
9 mm before BCG vaccination. A total of 87 (80.1%) of
the 107 persons with a negative QFT-TB test and TST ≥
15 mm were ethnical Norwegians.
Table 3 Contact investigations: exposure of tuberculosis
and QuantiFERON-TB Gold results compared with no
exposure.
TB case Exposure
No (% of total)
Pos QFT-TB
(% of risk group)
Household 42 (8.7) 59.5
Family outside household 41 (8.5) 19.5
Work 104 (21.6) 15.5
Friends/occupational 59 (12.3) 39.0
School 10 (2.1) 40.0
Aeroplane 5 (1.0) 0
No reported exposure 220 (45.7) 32.3
Figure 1 Relationship between Tuberculin skin test and
QuantiFERON-TB Gold responses. Corresponding tuberculin skin
test (mm) and QuantiFERON-TB Gold (QFT-TB, UI/ml) responses at
inclusion in patients with suspected tuberculous infection; positive
QFT-TB test (n = 122) and negative QFT-TB test (n = 308). The cut-
off for positive test is ≥ 0.35 IU/ml (solid line). Values > 10 IU/ml are
treated as 10 IU/ml due to inaccurately of the ELISA assay above
this level.
Table 4 QuantiFERON-TB Gold (QFT-TB) results in the
overall group of patients with a positive tuberculin skin
test (≥ 6 mm) and in various TST subgroups
TST Positive QFT-TB
Induration (mm) No (% of total) No (% of TST group)
≥ 6 398 (82.7) 127 (31.9)
0-5 37 (7.7) 1 (2.7)2
6-10 105 (21.8) 11 (10.5)
11-14 89 (18.5) 19 (21.3)
≥ 15 204 (42.4) 97 (47.5)3
No TST1 46 (9.6) 20 (43.5)
TST = tuberculin skin test. 1) Not tested due to previous strong response. 2)
Previous tuberculosis, 3) p < 0.001 compared to the other TST groups.
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The fraction of positive QFT-TB tests varied within
the various TB risk groups (Additional file 1). The per-
centage of positive test was highest in persons born in a
TB endemic country (111/166, 66.9%) or in those with
previous TB disease (20/28, 71.4%). The fraction of posi-
tive QFT-TB test in those reporting exposure for TB
was comparable with the study group in general. How-
ever, there was large variation within the various modes
of exposures with the highest fraction of positive QFT-
TB test found in the group exposed within the house-
hold (59.5%) and the lowest in the group exposed for
TB at work (15.5%) (Table 3).
Predictive factors for a positive QuantiFERON-TB Gold
test
In the multivariate logistic regression analysis, origin from
a TB endemic country (OR 6.82, 95% CI 1.73-26.82), dura-
tion of TB exposure (OR 1.59, 95% CI 1.14-2.22) and pre-
vious TB disease (OR 11.60, 95% CI 2.02-66.73) were all
independently associated with a positive QFT-TB test
(Additional file 1). Recent stay in a TB endemic country
expressed as years since last stay was associated with a
positive QFT-TB test (OR 1.32, 95% CI 1.09-1.59), while
visit to a TB endemic country was not. The percentage of
QFT-TB positive test was comparable in the groups with
and without BCG vaccination. However, there still seems
to be an association between BCG vaccination and a nega-
tive QFT-TB test (OR 0.13, 95% CI 0.03-0.66).
QuantiFERON-TB Gold responses during preventive
therapy for latent tuberculosis
Preventive therapy with isoniazid and rifampicin for three
months was started in 57 persons with suspected LTBI.
The decision to treat was made by the clinician and the
QFT-TB test was known at the time of decision. Only
one QFT-TB negative person was treated, a Norwegian
women with TST > 30 mm, previous long-term stay in a
TB endemic country and planned for therapy with a
TNF-a inhibitor. The other 56 initiating therapy were all
QFT-TB positive, representing 43% of the group with a
positive QFT-TB test. The majority of the treated had
origin from TB endemic countries, but 16 were Norwe-
gians tested as part of a contact investigation. All of the
treated, except four, had TST > 6 mm. The main reasons
for not giving preventive therapy to QFT-TB positive
individuals were older age, leaving the country, preg-
nancy or previous TB. Fifty persons received therapy for
a total of three months. Seven stopped therapy, predomi-
nantly due to side effects of the drugs.
Altogether 44 of the patients receiving preventive
therapy were available for repetitive QFT-TB tests. After
three months 87.5% were still QFT-TB positive (35/40
tested) whereas after 15 months, one year after the end
of therapy, 84.6% remained positive (22/26 tested). All
patients with reversed QFT-TB test after three months
were still negative at 15 months. No patient reverted
from positive to negative between three and 15 months
although one additional person was negative at month
15, but no test was performed at three months. All
negatives, except one, had low baseline IFN-g responses
(0.46-2.0 IU/ml). Compared to baseline, 44.7% showed a
decline while 55.3% had similar or stronger IFN-g
responses after three months (Figure 2). The corre-
sponding numbers after 15 months were 53.8% and
46.2%. By using an upper cut-off of the assay of 10
IU/ml, we found no significant difference in IFN-g
responses before (mean 6.13 IU/ml ± SD 3.99) and
after therapy (mean 5.65 IU/ml ± SD 3.66 vs. 5.65
IU/ml ± SD 4.14 after three and 15 months, respec-
tively), (p > 0.05). Repetitive testing after three months
of both QFT-TB positive and QFT-TB negative not
receiving therapy showed that of the seven QFT-TB
positive (0.40-10 IU/ml) tested, five were still positive
(0.41-10 IU/ml). All seven QFT-TB negative were still
negative.
Discussion
We present a longitudinal study performed in a regular
outpatient TB clinic in a TB low-endemic country. In
contrast to a number of studies focusing on particular
populations [2,4,5,11,25,26], we investigated the perfor-
mance of the QFT-TB test in various risk populations
referred according to present national guidelines [24]
and thus reflecting the clinical situation at a large size
Norwegian hospital. We further present data of IFN-g
responses during preventive therapy of latent TB.
Figure 2 QuantiFERON-TB Gold responses in latent
tuberculosis during preventive therapy. Interferon gamma
responses (IU/ml) before (baseline, n = 44), after three months (at
the end of therapy, n = 40) and after 15 months (one year after
ended therapy, n = 26) in patients with latent tuberculosis treated
with isoniazid and rifampicin.
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Risk factors for a positive QuantiFERON-TB Gold test
We show that the majority of the persons referred for
evaluation of TB based on a positive TST were QFT-TB
negative. If the diagnosis is based on a positive QFT-TB
test only 30% of the patients studied have TB infection.
We found that in a TB low-endemic country a positive
QFT-TB test is associated with origin from or short
time since stay in a TB endemic country. We observed
that although many ethnical Norwegians reported hav-
ing visited a TB endemic country, very few stayed for
longer periods and the majority of these were QFT-TB
negative. Our data support other studies, including the
Norwegian study of asylum seekers [25,27], and under-
scores the importance of screening asylum seekers for
TB at immigration.
Duration of TB exposure rather than exposure or not
was associated with a positive QFT-TB-test. Thus, we
found a very low fraction of positive QFT-TB tests in
the group exposed for TB at work in contrast to expo-
sure within the household. In our hospital setting expo-
sure-time seems to be short and low-risk due to proper
action during high-risk procedures [28]. Our findings
are partly in contrast to Vinton et al.’s study where
high-risk exposure, but not duration of exposure, was
associated with a positive test [25].
We found that previous TB diagnosis was also asso-
ciated with a positive QFT-TB test, which contrasts
findings by Winje et al. [27]. Over 70% of those with
previous TB still harboured a positive QFT-TB test
although anti-tuberculous therapy had been given to the
majority several years earlier. IGRA tests, based on short
time in vitro stimulation, are supposed to predominantly
measure effector T cells as indication of persistence of
TB antigens [29]. Still, the test does not allow discrimi-
nating between presence of latent or subclinical infec-
tion and TB specific immunological memory. Therefore,
our data do not support that IGRA-tests can be used to
discriminate between various stages of TB infection or
response to therapy. Finally, we found an association
between QFT-TB negative test and BCG vaccination.
This could be explained by the fact that almost 100% of
the ethnical Norwegians with low percentage of positive
QFT-TB test were vaccinated. An alternative explana-
tion is that vaccination in infancy protects against TB
infection [30].
In conclusion, recent immigrants from TB endemic
countries and those with long duration of exposure seem
to be most at risk for TB infection defined by a positive
QFT-TB test. Based on our calculations (data not shown)
a two-step approach seems to be most cost-effective when
screening for LTBI compared to the previous strategy
using TST alone. This is in agreement with other studies
[17,18,31], and our data has been used in the revised
national guidelines [7].
QuantiFERON-TB Gold and Tuberculin skin test responses
The number of QFT-TB positive tests increased with
increasing TST values, although we have not performed
a direct comparison between TST and QFT-TB, since a
positive TST was one of the major criteria for referring
the patients. Only 2.7% (one with previous active TB)
and 10.5% had a positive QFT-TB test in individuals
with TST < 6 mm and < 11 mm, respectively. This is
comparable with earlier studies of contact investigations
including the Norwegian study of asylum seekers
[27,32,33]. Our data also supports a German study that
found that TST-/QFT+ discordance increased with age
[34], and indicate that the QFT-TB test might be more
sensitive than TST in the elderly.
TST ≥ 15 mm has previously been considered true TB
infection [21,35] and has been shown to correlate to pro-
gression of active disease [36,37]. However, only 47.5% of
the individuals with such strong TST responses had a posi-
tive QFT-TB test. There is no certain explanation for this
discordance [38-41]. The clinical effect of NTMs on TST is
normally minimal, except in parts of the world where TB
prevalence is low and NTMs more common due to moist
climate [21]. It is of interest that of those 107 persons with
TST ≥ 15 mm and negative QFT-TB tests only twenty
were from TB endemic countries. Since very small effects
of BCG on TST reactions are expected after 10 years for
people vaccinated in infancy [21], this might represent false
negative QFT-TB tests [6]. Still, our data indicate that BCG
vaccination, boosting of immune responses by repetitive
testing [42] or infections with NTMs [21] are responsible
for the vast majority of false positive TST. Nevertheless,
lack of diagnostic gold standard for LTBI emphasises the
need for follow-up of individuals with strong TST reactions
and risk factors for TB infection.
QuantiFERON-TB Gold responses during preventive
therapy for latent tuberculosis
The effect of standard three months preventive TB
treatment on QFT-TB was only modest with 85% still
positive both shortly after and one year after ended
therapy. The few cases with negative conversion had
predominantly low values at baseline. In contrast, cases
with strong responses ≥ 10 IU/ml more often persisted.
The prognostic use of IGRA tests as marker for
response to therapy is not established and data are con-
flicting, performed in various endemic settings and with
different IGRAs and upper and lower cut-off levels.
Most studies have been performed on patients treated
for active TB [43-52]. Pai et al. show persistence of
QFT-TB responses during treatment [48]. In contrast,
Katiyar et al. found that only 48% were positive by the
same assay after 6 months [51]. Also studies of T-
SPOT.TB are conflicting as Dheda et al. report 81%
with negative test in late phase therapy of patients with
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active TB [49]. The corresponding numbers in Ribeiro
et al’s study is only 10% [52]. Studies of LTBI are lim-
ited and data are conflicting also in this group lacking
the diagnostic gold standard for comparison [13-16].
Our study is performed in a low transmission setting
with little likelihood of reinfection. Further, the patients
were also treated in a DOTs regimen ensuring a good
compliance to therapy. Combined this indicates that
persistent positive QFT-TB tests represent persistence
of pre-treatment IFN-g responses.
Around half of the patients experienced a decline,
while the other half maintained strong IFN-g responses.
However, all patients were still healthy 15 months after
preventive therapy with no signs of active TB. Although
it has been proposed that IGRA tests could identify
those who will progress to active TB [53], in the study
by Diel et al. only the minority of the QFT-TB positive
individuals recently exposed developed active disease
during the two years follow-up [19].
The interpretation of serial testing of IGRA tests is
controversial. For the baseline QFT-TB we performed
dual testing of the same sample with almost 100%
reproducibility (data not shown). Unfortunately we were
not able to repeat systematically the QFT-TB test for all
positive not treated or for the QFT-TB negative group,
but our limited data indicate an overall good intra-assay
reproducibility over time although two converted from
low-level positive values to negative. Still, low-level posi-
tive QFT-TB tests need to be interpreted with caution
as transient responses to QFT-TB are quite common
[54] and positive results can vary over time [55]. Thus,
we can not for sure conclude that the reversion of QFT-
TB from positive to negative were due to the effect of
therapy since some of the cases had low baseline values.
Finally, although TST originally has been considered not
to boost IGRA responses, data has been conflicting
[56,57]. A recent report demonstrates that this could
occur up to three months after TST [58]. In our study
TST testing in the primary health care system was per-
formed in the majority of cases at least three months
prior to the QFT-TB testing minimising this effect. Still,
small variations around the cut-off values should be
treated with caution when deciding for LTBI therapy
and new cut-offs might be validated.
In conclusion, our data indicate that IGRA tests
should not be used for the individual as a reliable mar-
ker to monitor the effect of therapy.
Performance of the QuantiFERON-TB Gold test in an
outpatient clinical setting
The performance of the QFT-TB test was good in this
clinical setting. All 15 diagnosed with active TB had a
positive QFT-TB test giving a sensitivity of 100% and a
high agreement with TST. The sensitivities of both TST
and IGRA tests in larger studies of active TB are in the
range of 75-90% depending of the assay [6]. Although a
much too small number to conclude, our data suggest
that patients with active TB diagnosed in an outpatient
clinical setting might possess a less advanced stage of
disease with preserved reactivity to TB antigens.
We got no indeterminate results although more than
13% of the participants were tested before treatment with
a TNF-a inhibitor and assumed to have suppressed
immune systems to various extents. We have in our diag-
nostic laboratory later experienced approximately 10%
indeterminate results in immunocompromised patients
(unpublished data). The only HIV positive included had a
rather high CD4 count and tested positive with the QFT-
TB test. HIV testing was decided by the clinician and has
traditionally not been performed in our TB outpatient
clinic. However, the lack of routinely HIV testing is a
limitation in our study as it is well known that IGRA
tests could be inconclusive in immunocompromised
patients, especially with CD4 count under 100 [9,26].
Although the T-SPOT.TB assay appears to give higher
sensitivity and rates of conclusive tests than the QFT-TB
test [6], one must be aware of the limitations of both
IGRA tests in patients with suppressed immune system.
Conclusion
The number of TB infected based on a positive QFT-TB
test seems to be only one third of that based on a positive
TST. Recent stay or origin from TB endemic countries
and long duration of exposure seems to be risk factors for
LTBI and thus these groups should be targeted through
screening. Most patients with LTBI were still QFT-TB
positive after preventive therapy and the test should not
be used as a reliable marker to monitor the effect of ther-
apy. Prospective studies are needed in order to understand
the kinetic of IFN-g responses and determine the useful-
ness of IGRA tests as diagnostic tool during therapy.
Additional file 1: Predictors for positive QuantiFERON-TB Gold test
(QFT-TB). Multivariate analysis performed by logistic regression. * P-value
< 0.05, **P-value < 0.001. CI: confidence intervals, OR: odd ratios. Age
was categorised as 9-19 years, 20-29 years, 30-39 years, 40-49 years, 50-59
years and ≥ 60 years. Recent stay in a TB endemic country, recent
exposure of TB and recent vaccination were all categorised as time since
last event (<1 year, 1 to <2 years, 2 to <3 years, 3 to <5 years, 5 to <10
years, 10 to <20 years and then in 10 year intervals). Duration of
exposure was categorised as <1 day, 1 to 6 days, 1 to <4 weeks, 1 to <2
months, 2 to <3 months, ≥ 3 months. Some numbers do not add up to
481 for all characteristics due to unknown parameters for some
participants. The number of observations available for each variable and
the total number of observations (no = 389) included in the final logistic
regression model are as given in brackets.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2334-10-
57-S1.DOC ]
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